Search
Publications & Presentationsbreadcrumb separatorPublicationsbreadcrumb separatorPublic Healthbreadcrumb separator2017
Publications 2017
1.  Restrictions for reimbursement of interferon-free direct-acting antiviral therapies for HCV infection in Europe. A Marshall, EB Cunningham, S Nielsen, A Aghemo, H Alho, M Backmund, B Bruggmann, O Dalgard, C Seguin-Devaux, R Flisiak, GR Foster, L Gheorghe, D Goldberg, I Goulis, M Hickman, P  Hoffmann, L Jancorienė, P Jarcuska, M Kåberg, LG Kostrikis, M Makara, M Maimets, RT Marinho, M Matičič, S Norris, S Ólafsson, A Øvrehus, JM Pawlotsky, J Pocock, G Robaeys, C Roncero, M Simonova, J Sperl, M Tait, I Tolmane, S Tomaselli, M van der Valk, A Vince, GJ Dore, JV Lazarus, and J Grebely.
Lancet Gastro Hep, 2017. Abstract

2.  Associations between national viral hepatitis policies/programmes and country-level socioeconomic factors: a sub-analysis of data from the 2013 WHO viral hepatitis policy report. JV Lazarus, I Sperle, K Safreed-Harmon, C Gore, B Cebolla, A Spina..
BMC Public Health, July 2017. Abstract

3.  Monitoring quality and coverage of harm reduction services for people who use drugs: a consensus study. L Wiessing, M Ferri, V Běláčková , P Carrieri, SR Friedman, C Folch, K Dolan, B Galvin, P Vickerman, JV Lazarus, V Mravčík, M Kretzschmar, V Sypsa, A Sarasa-Renedo, A Uusküla, D Paraskevis, L Mendão, D Rossi, N van Gelder, I Mitcheson, L Paoli, CD Gomez, M Milhet, N Dascalu, J Knight, G Hay, E Kalamara, R Simon; EUBEST working group, C Comiskey, C Rossi,P Griffiths. Harm Reduct J. 2017 Apr 22;14(1):19. Abstract

4.  Restrictions on access to direct-acting antivirals for people who inject drugs: The European Hep-CORE study and the role of patient groups in monitoring national HCV responses. JV Lazarus, K Safreed-Harmon, SR Stumo, M Jauffret-Roustide, M Maticic, T Reic, E Schatz, J Tallada, M Harris, on behalf of the Hep-CORE Study Group.
Int J Drug Policy, 2017; 14;47-50. Abstract

5.  Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs. J Grebely, J Bruneau, JV Lazarus, J Byrne, L Crooks, O Dalgard, P Bruggmann, C Treloar, M Hickman, M Hellard, T Roberts, L Crooks, H Midgard, S Larney, L Degenhardt, H Alho, J Byrne, J Dillon, JJ Feld, G Foster, D Goldberg, J Khalsa, A Lloyd, J  Reimer, G Robaeys, M Torrens, N Wright, B Norton, A Litwin, G Dore, on behalf of the International Network on Hepatitis in Substance Users.
Int J Drug Policy, 2017, 47: 51-60. Abstract

6.  Associations between national viral hepatitis policies/programmes and country-level socioeconomic factors: a sub-analysis of data from the 2013 WHO viral hepatitis policy report. JV Lazarus, I Sperle, K Safreed-Harmon, C Gore, B Cebolla, A Spina.
BMC Public Health, 2017, 18(1):16. Abstract

7.   Micro-elimination – a path to global elimination of hepatitis C. JV Lazarus, SZ Wiktor, M Colombo, M Thursz..
Journal of Hepatology, July 2017; 67(4): 665-666. Abstract

8.  Monitoring quality and coverage of harm reduction services for people who use drugs: a consensus study. L Wiessing, M Ferri, V Běláčková, P Carrieri, SR Friedman, C Folch, K Dolan, B Galvin, P Vickerman, JV Lazarus, V Mravčík, M Kretzschmar, V Sypsa, A Sarasa-Renedo, A Uusküla, D Paraskevis, L Mendão, D Rossi, N van Gelder, L Mitcheson, L Paoli, CD Gomez, M Milhet, N Dascalu, J Knight, G Hay, E Kalamara, R Simon; EUBEST working group, C Comiskey, C Rossi, P Griffiths. 
Harm Reduct J. 2017;14(1):19. Abstract

9.  Commentary on Trias-Llimos et al. (2017): Birth cohort research— an essential tool to guide public health interventions. JV Lazarus, D Bromberg.
Addiction, 2017; 112(2):259-260. Abstract

10. Hepatitis B virus in drug users in France: prevalence and vaccination history, ANRS-Coquelicot Survey 2011-2013. M Molinier, C Brouard, P Sogni, F Barin, JV Lazarus, X Pascal, J Pillonel, M Jauffret-Roustide and the ANRS Coquelicot Study-Group.
Epidemiology and Infection, 2017 :1-11. Abstract

11. Policy responses to hepatitis C in the Nordic countries: Gaps and discrepant reporting in the Hep-Nordic study. K Safreed-Harmon, K.L Hetherington, S Aleman, H Alho, O Dalgard, T Frisch, M Gottfredsson, N Weis, J.V. Lazarus & Hep-Nordic Study Group.
 P L o S One, 2018: 13, 11. Abstract